This seminar will provide an overview of the CRISPR IP saga,
discussion of considerations in relation to freedom-to-operate for
use of the technology and an update on the lessons to be learnt
from the IP issues which have inflicted major costs on those
involved.
Thursday 27th June, Der Teufelhof Basel, 6pm
CRISPR gene-editing continues to hit headlines regularly as a
ground-breaking technology with many millions now flowing into
companies seeking to exploit the technology in both therapeutic and
agricultural fields. Unfortunately the corresponding IP landscape
still has many issues to be resolved with possibility of divergence
between Europe and the US.
This seminar will provide an overview of the CRISPR IP saga,
discussion of considerations in relation to freedom-to-operate for
use of the technology and an update on the lessons to be learnt
from the IP issues which have inflicted major costs on those
involved.
